

Prescribing Clinical Network

<b>Policy Statement</b>	Biosimilar enoxaparin use for all licensed indications in adults
<b>Policy No:</b>	PCN 319-2018
<b>Date of Issue</b>	January 2018
<b>Review Date:</b>	January 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<b>Recommendations:</b> <p>Enoxaparin is a biological medicine and must be prescribed by brand in line with MHRA guidance.</p> <p><i>Note: differences in the mechanism for operation of the needle guard between presentations of enoxaparin.</i></p>	
<b>Key Consideration:</b> <ul style="list-style-type: none"> <li>The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends that it is good practice to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist.</li> <li><a href="http://www.sps.nhs.uk">www.sps.nhs.uk</a> Specialist Pharmacy Service – In use product safety assessment report for Inhixa® (enoxaparin Biosimilar) <a href="https://www.sps.nhs.uk/articles/in-use-product-safety-assessment-report-for-inhixa-enoxaparin-biosimilar/">https://www.sps.nhs.uk/articles/in-use-product-safety-assessment-report-for-inhixa-enoxaparin-biosimilar/</a></li> </ul>	
<b>Date taken to Prescribing Clinical Network</b>	10 <sup>th</sup> January 2018
<b>Agreed by PCN members</b>	7 <sup>th</sup> February 2018